Metsera (NASDAQ:MTSR) Now Covered by Evercore ISI

Evercore ISI started coverage on shares of Metsera (NASDAQ:MTSR) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The firm set an “outperform” rating on the stock.

Metsera Stock Performance

NASDAQ:MTSR opened at $27.21 on Tuesday. Metsera has a one year low of $25.06 and a one year high of $32.81.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.